Adulterated OTCs Reach Dollar Tree, Third-Party Test Lab Missed Problems
Executive Summary
Warning links retailers to multiple manufacturers inspected after FDASIA in 2012 pointed FDA toward inspecting all ex-US firms supplying products available in US but that had yet to be inspected for compliance. Manufacturers also were placed on import alerts to prevent their products, including cosmetics as well as drugs, from reaching US.
You may also be interested in...
US Health Market In 2019: Unfinished Business Leaves Lasting Impression
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
FDA’s Record-Number GMP Warnings In FY 2019 Included First Of A Kind
Total GMP warnings in FY19 was 98, more than half to US firms. Warning to Dollar Tree “should serve as a reminder that although distributors may not be subject to CGMP requirement themselves, they are responsible for ensuring the drugs they distribute into interstate commerce are not adulterated,” says CDER compliance chief Donald Ashley.
US FDA Warns Second Ningbo, China, OTC Firm In Two Weeks On Violations
Hand sanitizer, shampoo, acne scrub, other products available in US under brands including AuraFresh, Halsa, Spa Mystique deemed adulterated due to GMP problems found during an inspection at Pulisi Daily's facility in city in Zhejiang Province.